Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
June 26, 2023 07:00 ET
|
Trevena, Inc.
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated...
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
May 31, 2023 07:00 ET
|
Trevena, Inc.
$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first...
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones
May 30, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports First Quarter 2023 Results and Provides Business Update
May 15, 2023 07:00 ET
|
Trevena, Inc.
OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million...
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
May 09, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Approval of OLINVYK in China
May 08, 2023 07:00 ET
|
Trevena, Inc.
Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15...
Trevena to Participate in Three Upcoming Conferences
May 03, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
March 30, 2023 07:02 ET
|
Trevena, Inc.
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on...
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
March 30, 2023 07:00 ET
|
Trevena, Inc.
Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor...
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
March 27, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...